201 related articles for article (PubMed ID: 24100437)
1. A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors.
Gong H; Kovar JL; Cheung L; Rosenthal EL; Olive DM
Cancer Biol Ther; 2014 Feb; 15(2):185-93. PubMed ID: 24100437
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
[TBL] [Abstract][Full Text] [Related]
3. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
5. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
[TBL] [Abstract][Full Text] [Related]
7. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.
Day KE; Sweeny L; Kulbersh B; Zinn KR; Rosenthal EL
Mol Imaging Biol; 2013 Dec; 15(6):722-9. PubMed ID: 23715932
[TBL] [Abstract][Full Text] [Related]
8. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
Yang W; Barth RF; Wu G; Ciesielski MJ; Fenstermaker RA; Moffat BA; Ross BD; Wikstrand CJ
Clin Cancer Res; 2005 Jan; 11(1):341-50. PubMed ID: 15671565
[TBL] [Abstract][Full Text] [Related]
9. In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores.
Sano K; Mitsunaga M; Nakajima T; Choyke PL; Kobayashi H
Breast Cancer Res; 2012; 14(2):R61. PubMed ID: 22510481
[TBL] [Abstract][Full Text] [Related]
10. Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments.
Bernhard W; El-Sayed A; Barreto K; Gonzalez C; Fonge H; Geyer CR
Theranostics; 2019; 9(4):974-985. PubMed ID: 30867810
[TBL] [Abstract][Full Text] [Related]
11. Photoacoustic Molecular Imaging for the Identification of Lymph Node Metastasis in Head and Neck Cancer Using an Anti-EGFR Antibody-Dye Conjugate.
Nishio N; van den Berg NS; Martin BA; van Keulen S; Fakurnejad S; Rosenthal EL; Wilson KE
J Nucl Med; 2021 May; 62(5):648-655. PubMed ID: 33008927
[TBL] [Abstract][Full Text] [Related]
12. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
Niu G; Li Z; Xie J; Le QT; Chen X
J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473
[TBL] [Abstract][Full Text] [Related]
13. Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.
Nishio N; van den Berg NS; van Keulen S; Martin BA; Fakurnejad S; Zhou Q; Lu G; Chirita SU; Kaplan MJ; Divi V; Colevas AD; Rosenthal EL
Mol Imaging Biol; 2020 Feb; 22(1):156-164. PubMed ID: 31054001
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III.
Fukai J; Nishio K; Itakura T; Koizumi F
Cancer Sci; 2008 Oct; 99(10):2062-9. PubMed ID: 19016767
[TBL] [Abstract][Full Text] [Related]
15. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
